Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
IPO Year: 2021
Exchange: NASDAQ
Website: movano.com
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
8-K - Movano Inc. (0001734750) (Filer)
10-Q - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
424B5 - Movano Inc. (0001734750) (Filer)
S-8 - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
10-Q - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
SC 13G - Movano Inc. (0001734750) (Subject)
SC 13G/A - Movano Inc. (0001734750) (Subject)
SC 13G - Movano Inc. (0001734750) (Subject)
SC 13G - Movano Inc. (0001734750) (Subject)
Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto
Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device
Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco
Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report second quarter 2024 financial and operating results on Wednesday, August 14, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The c
Submits exemplary Sp02 clinical trial results as part of FDA 510(k) clearance processPlans launch of Evie Med and focuses on B2B opportunitiesPlans arterial blood pressure study for JuneConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., May 15, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported first quarter 2024 results and provided a business update. Following the successful close of its recent $24 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device company, Movan
Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., May 6, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report first quarter 2024 financial and operating results on Wednesday May 15, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The confere
Financing included a strategic seed investment by a tier-1 multi-billion dollar medical device company and participation from members of Movano Health's management team and board of directors Hosting conference call on April 4, 2024 at 2:00 PM PT/5:00 PM ET PLEASANTON, Calif., April 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today has agreed to sell approximately 45 million units in a $24 million private placement, with each unit consisting of one share of the Company's common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase a share of common stock, to a select group of investors that includes a tier-one multi-billion dolla
Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., April 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report fourth quarter 2023 financial and operating results on Thursday, April 4, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The con
PLEASANTON, Calif., Aug. 8, 2023 /PRNewswire/ -- Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices and makers of the Evie Ring, today announced that it will report second quarter 2023 financial and operating results on Monday, August 14, 2023. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 2:00 p.m. PDT (5:00 p.m. EDT). Attendees can access the live webcast here or on the investors section of Movano Health's webs
Conference call begins at 2:00 p.m. Pacific time today PLEASANTON, Calif., Nov. 14, 2022 /PRNewswire/ -- Today, Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medical and consumer devices, reported financial results for the three months ending September 30, 2022 and provided a business update. Highlights from the third quarter and recent weeks include the following: Movano Health continues to expect to test the wearability and functionality of its smart device in beta programs with multiple strategic partners b
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
3 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
New proprietary RF hardware delivers significantly enhanced signal fidelity PLEASANTON, Calif., Feb. 4, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE) announced today that it has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist wearable. The study, which is expected to include at least 70 participants and be completed during the second week of February, utilizes the updated device to monitor pulse pressure waveforms in comparison with a hospital grade blood pressure device. The new wearable will also collect data on a host of other vital signs including pulse rate, blood oxygen saturation (SpO2), respiration rate and ECG waveforms.
Newest Evie Ring feature is the first medical journal trained AI companion in a wearable PLEASANTON, Calif., Jan. 8, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced the latest enhancement to its Evie smart ring for women with the beta release of EvieAI, the first wearable-based virtual wellness assistant trained exclusively with data from medical journals. The new feature enables Evie users to answer health questions quickly, reliably and securely through the ring's companion app. Planned future integration with Evie data will allow EvieAI's responses to be p
PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced the expansion of its board of directors with the addition of Dr. Shaheen Wirk, a leader in healthcare dedicated investment with a track record of success in medicine, partnerships, and research. With over 20 years of investment experience in public and private life science companies, Dr. Wirk is the founder and Chief Investment Officer of Palkon Capital Management, a healthcare dedicated investment firm launched in partnership with Julian Robertson and
Company's first 510(k) clearance unlocks a TAM of $40 billion in healthcare B2B opportunities PLEASANTON, Calif., Dec. 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the pulse oximeter in its EvieMED Ring. The clearance enables Movano Health to pursue multi-billion dollar business opportunities for health monitoring solutions needed for applications such as clinical trials, post-clinical trial management, and remote patient monitoring for both healthcare providers and payors.
Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto
New hardware boasts significant improvements to reduce noise and generate higher fidelity signals PLEASANTON, Calif., Nov. 7, 2024 /PRNewswire/ -- Movano Health Inc. (NASDAQ:MOVE) announced today that it has tested its newly developed blood pressure wrist wearable as part of its November 5th and 6th hypoxia clinical trial that took place at the University of California, San Francisco. The updated device features an additional 12 mmWave antennas which together with Movano Health's custom IC delivers enhanced data collection with less impact of placement while also featuring a slimmer design, making it easier and more comfortable to wear. In addition, the new wearable monitors a host of other
Company Continues to Work with Securities Regulators, Legal Advisors and Other Partners to Protect Interests of Shareholders PLEASANTON, Calif., Nov. 4, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) (the "Company") provided an update on an investigation to expose apparent manipulation in trading of the Company's common shares, following the recent announcement of a shareholder approved reverse stock split. Based on its preliminary investigation, the Company believes that between the announcement of the reverse split on October 25, 2024, and its effective date on October 2
Company remains optimistic on the potential for this pioneering healthcare solution PLEASANTON, Calif., Nov. 4, 2024 /PRNewswire/ -- Movano Health (NASDAQ: MOVE) announced today that it has submitted a complete response package to the FDA as part of the final phase of the Company's 510(k) application review of the EvieMED Ring. The Company remains optimistic on EvieMED's potential for 510(k) clearance. "Our team has worked diligently to provide a thorough response to the Agency's questions," said John Mastrototaro, President and CEO of Movano Health. "We look forward to the su
Company Communicating with Securities Regulators, Legal Advisors and Other Partners to Protect Interests of Shareholders PLEASANTON, Calif., Oct. 31, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) (the "Company") announced today that it has opened an investigation to expose apparent manipulation in trading of the Company's common shares, following the recent announcement of a shareholder approved reverse stock split. "We are committed to transparency and protecting the interests of our Company and shareholders," said John Mastrototaro, President and CEO of Movano Health. "
Collaboration Will Expand Awareness of Movano's Female First Wearable to D'Amelio's 12 Million Social Media Followers PLEASANTON, Calif., Oct. 30, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE) today announced its first brand partnership with digital creator, wife, mom and entrepreneur Heidi D'Amelio. An icon in the wellness, fashion and beauty space, D'Amelio will share her experiences with Movano's Evie Ring with her more than 12 million Instagram and TikTok followers and also provide product feedback to help the Movano team fine-tune its roadmap for ongoing upgrades to the Evie app.